Hublo, a Paris-based provider of workforce management software solutions for the healthcare sector, has raised received a €40 million reinvestment vehicle from growth investment firm Revaia.
This investment will support Hublo in a new phase following its sale in 2025, aiming to extend support for the company beyond the initial holding period.
This follows 2025’s close of Revaia Growth II fund at €250 million, as covered by EU-Startups.com.
Antoine Loron, co-founder and co-CEO of Hublo, added: “Revaia’s continued commitment to us is a continuation of a long-term partnership built on trust and alignment. Their decision to reinvest alongside our new majority shareholder demonstrates their belief in our trajectory and strengthens the stability of our shareholder base for the next stage of our development.”
Activity across 2025 and early 2026 points to continued but generally smaller-scale investment activity across adjacent areas of European HealthTech when compared with Hublo’s €40 million reinvestment.
In September 2025, Warsaw-based Doctor.One raised €4 million to expand its asynchronous care platform for chronic patients into additional European markets, while Antwerp startup Mindoo secured €5 million in Seed funding to reduce administrative workload for hospital and medical staff using AI agents, placing it closest thematically to Hublo’s focus on operational efficiency for healthcare professionals. In Switzerland, Zurich-based Ahead Health raised €5.1 million to scale its preventive healthcare services through clinic partnerships, while UK longevity startup GlycanAge closed a €7.4 million round to commercialise glycan-based ageing diagnostics.
Taken together, these adjacent healthtech rounds amount to approximately €21.5 million, underscoring that Hublo’s reinvestment vehicle is materially larger than most recent European HealthTech financings and reflects a later-stage, ownership-driven commitment rather than primary growth capital alone.
Alice Albizzati, Founding Partner of Revaia, stated: “This reinvestment vehicle extends the support we have provided to Hublo since 2021 and reflects our confidence in the quality of the team and the company’s trajectory, while also allowing us to bring in new investors for the next phase of value creation.”
Founded in 2016, Hublo was born from the merger of Whoog and MedGo during the height of the Covid crisis – addressing structural healthcare staff shortages. Its platform enables healthcare institutions to efficiently manage staffing, from recruitment to scheduling, internal mobility, and communication.
The solution reportedly centralises and optimises the ad-hoc and recurring staffing needs of hospitals, clinics, nursing homes, and healthcare providers. By 2025, Hublo was being used by over 22,000 managers in more than 5,000 facilities, benefiting 1 million healthcare professionals, with an average saving of 2.5 hours per day per user.
Having acquired a significant stake in July 2021, when Hublo was already establishing itself as a player in the digitalisation of workforce management for healthcare facilities, Revaia supported the company in its expansion and scaling-up strategy.
This support was structured around three key levers:
- Extending the product offering to a comprehensive workforce and talent management platform
- Strengthening the go-to-market strategy with public and private institutions
- Implementing a proactive sector consolidation strategy, which included three acquisitions that were integrated during this period.
This momentum enabled Hublo to quadruple its annual recurring revenue and reach operational break-even ahead of schedule. Five Arrows, the alternative asset investment arm of Rothschild & Co, finalised its strategic investment in July 2025 following a competitive process. This sale marks the first exit for the Revaia Growth I fund.
The reinvestment vehicle raised by Revaia brings together European, UK and US investors and allows both existing Revaia investors and new entrants to invest alongside the new shareholder and management team.
Read the orginal article: https://www.eu-startups.com/2026/02/healthtech-platform-hublo-secures-e40-million-revaia-reinvestment-to-support-post-exit-growth-phase/
